Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, April 29, 2022
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
[ Fri, Apr 29th 2022
] - WOPRAI
David Lebowitz Maintained (ALNY) at Strong Buy with Decreased Target to $211 on, Apr 29th, 2022
David Lebowitz of Citigroup, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy with Decreased Target from $223 to $211 on, Apr 29th, 2022.
David has made no other calls on ALNY in the last 4 months.
There are 3 other peers that have a rating on ALNY. Out of the 3 peers that are also analyzing ALNY, 0 agree with David's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with David
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $400 on, Tuesday, April 12th, 2022
- Etzer Darout of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $170 on, Thursday, February 3rd, 2022
- Edward Tenthoff of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $208 on, Monday, January 3rd, 2022
